The research company Chosa Oncology announces that the company will present data on the biomarker Platin-DRP at the lung cancer congress ELCC in Köpenhamn on March 26. The analysis is based on a Phase III study and evaluates associations between the biomarker and clinical outcomes in treatment with platinum-based drugs.The results concern patients with advanced non-small cell lung cancer and will be presented in a poster session. Complete data will be made public in connection with the presentation.